As a member of Penn's LSM program, Katherine completed her Bachelors’ in both Biochemistry and Finance. She interned in both academia and industry, including biotech, during her summers. Outside of school, Katherine was also involved in coordinating the Biochemistry Seminar Speaker Series and Wharton Leadership Ventures. Afterwards, Katherine joined the M&A team at Citigroup as an Analyst. In that time, she worked with the industry-agnostic product group on a variety of deals spanning telecommunications, industrials, transport, datacenters, consumer, and healthcare. From there, Katherine returned to New Jersey to the Graduate School at Princeton to join the Molecular Biology Department. Katherine is currently working towards her PhD in the Lewis Sigler Institute for Genomics, studying cognitive aging and germline-to-neuron signaling pathways in the model organism, C. elegans.

‍

What is a healthcare advancement you hope to see in your lifetime?

Treatment for high-burden indications in the CNS field. While scientific, financial, and regulatory barriers exist still in targeting the brain in devastating brain disorders, I hope to see this healthcare advancement in my lifetime."

‍

What excites you most about working with ARTIS?

At ARTIS, I'm really excited to work alongside the team to contribute to diligence and meet founders. I hope to learn a lot regarding new areas of Tech Bio+Health and understand the strategy behind programs in the AV ecosystem."
‍

What is the most influential content you read last year?

Mountains Beyond Mountains by Tracy Kidder. A biography of Dr. Paul Farmer's life and work in public health.